Wild type p53 reactivation: From lab bench to clinic

被引:59
|
作者
Selivanova, Galina [1 ]
机构
[1] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, SE-17177 Stockholm, Sweden
来源
FEBS LETTERS | 2014年 / 588卷 / 16期
基金
瑞典研究理事会;
关键词
p53; Small molecule; Mdm2; MdmX; Apoptosis; ROS; SMALL-MOLECULE RITA; P53-MEDIATED TUMOR SUPPRESSION; UBIQUITIN LIGASE ACTIVITY; RNA-POLYMERASE I; CANCER-THERAPY; MUTANT P53; DNA-DAMAGE; EMBRYONIC LETHALITY; MDM2; INHIBITOR; GROWTH ARREST;
D O I
10.1016/j.febslet.2014.03.049
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The p53 tumor suppressor is the most frequently inactivated gene in cancer. Several mouse models have demonstrated that the reconstitution of the p53 function suppresses the growth of established tumors. These facts, taken together, promote the idea of p53 reactivation as a strategy to combat cancer. This review will focus on recent advances in the development of small molecules which restore the function of wild type p53 by blocking its inhibitors Mdm2 and MdmX or their upstream regulators and discuss the impact of different p53 functions for tumor prevention and tumor eradication. Finally, the recent progress in p53 research will be analyzed concerning the role of p53 cofactors and cellular environment in the biological response upon p53 reactivation and how this can be applied in clinic. (C) 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:2628 / 2638
页数:11
相关论文
共 50 条
  • [1] Study on The Mechanism of Reactivation of Mutant p53 to Wild-type-like p53 by Andrographolide
    Song Bin
    Wang Jia-Jian
    Su Yong-Nan
    Wang Yu-Ling
    Yang Fan
    Zhang Ji-Hong
    [J]. PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2022, 49 (09) : 1763 - 1773
  • [2] The p53 tumor suppressor gene: From the bench top to the clinic
    Chang, S
    Wills, K
    Demers, GW
    Engler, H
    Nielsen, L
    Johnson, D
    Horowitz, J
    Maneval, D
    [J]. CANCER GENE THERAPY, 2000, 7 (08) : 1209 - 1209
  • [3] Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis
    Hiraki, Masatsugu
    Hwang, So-Young
    Cao, Shugeng
    Ramadhar, Timothy R.
    Byun, Sanguine
    Yoon, Kyoung Wan
    Lee, Jung Hyun
    Chu, Kiki
    Gurkar, Aditi U.
    Kolev, Vihren
    Zhang, Jianming
    Namba, Takushi
    Murphy, Maureen E.
    Newman, David J.
    Mandinova, Anna
    Clardy, Jon
    Lee, Sam W.
    [J]. CHEMISTRY & BIOLOGY, 2015, 22 (09): : 1206 - 1216
  • [4] Wild type and mutant p53 functions
    Lozano, Guillermina
    [J]. CANCER SCIENCE, 2022, 113 : 1227 - 1227
  • [5] Contribution of the p53 pathway in cancers that carry wild-type p53
    Ohki, Rieko
    [J]. CANCER SCIENCE, 2022, 113 : 1232 - 1232
  • [6] Genistein protects p53 wild type cells from taxol
    Tokalov, Sergey
    Gerlach, Michael
    Abramyuk, Andrij
    Wolf, Gunter
    Abolmaali, Nasreddin
    [J]. CELLULAR ONCOLOGY, 2008, 30 (02) : 182 - 183
  • [7] COTRANSLATION OF ACTIVATED MUTANT P53 WITH WILD-TYPE DRIVES THE WILD-TYPE P53 PROTEIN INTO THE MUTANT CONFORMATION
    MILNER, J
    MEDCALF, EA
    [J]. CELL, 1991, 65 (05) : 765 - 774
  • [8] Mutant p53 reactivation by small molecules makes its way to the clinic
    Bykov, Vladimir J. N.
    Wiman, Klas G.
    [J]. FEBS LETTERS, 2014, 588 (16): : 2622 - 2627
  • [9] TUMOR SUPPRESSOR P53 - ANALYSIS OF WILD-TYPE AND MUTANT P53 COMPLEXES
    MILNER, J
    MEDCALF, EA
    COOK, AC
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1991, 11 (01) : 12 - 19
  • [10] The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53
    E Drakos
    V Atsaves
    E Schlette
    J Li
    I Papanastasi
    G Z Rassidakis
    L J Medeiros
    [J]. Leukemia, 2009, 23 : 2290 - 2299